Search

Psoriasis is a multifactorial, chronic, auto‐ inflammatory disease, with a worldwide prevalence of around 2%, subtended by robust genetic predisposition and autoimmune pathogenic traits. The disease, mainly involving the skin and joints, is featured by erythemato‐squamous lesions, with a chronic relapsing course and relevant systemic comorbidities. Apremilast is a novel oral agent that has recently been made available to dermatologists for the treatment of moderate‐to‐severe plaque psoriasis and psoriatic arthritis. Although it is considered as relatively safe molecule with few contraindications, experience with Apremilast in the real‐world setting for cancer patients with moderate‐to‐severe plaque psoriasis is lacking. Hence, we report the real‐life experience in patients with psoriasis and a history of cancer who underwent treatment with Apremilast for 104 weeks. [ABSTRACT FROM AUTHOR]

At 16 weeks, more patients reached an ACR50 response in the treatment groups than in the placebo groups (44% versus 10% for the BE OPTIMAL trial; 43% versus 7% for the BE COMPLETE trial). Dual inhibition of IL-17A and IL-17F with bimekizumab leads to superior improvements in joint and skin outcomes compared with placebo in patients with active psoriatic arthritis who are either naive to biologic DMARDs or who have had a previous inadequate response or intolerance to TNF inhibition, according to results from the BE OPTIMAL and BE COMPLETE phase III clinical trials. Bimekizumab in patients with active psoriatic arthritis, naïve to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL). [Extracted from the article]

The article offers information on several drugs including the Apremilast, an anti-inflammatory drug, from Celgene Corp., the Avanafil for penile dysfunction from Vivus Inc. and the Perampanel antiepileptic drug from Eisai Inc.

The article previews the IMRALDI (adalimumab) biosimilar drug from Samsung Bioepis Co., Ltd. and Biogen.

The article offers information on new drugs including Apremilast tablets from Otezla, Metronidazole vaginal gel from Valeant Pharmaceuticals and Miltefosine capsules from Paladin Therapeutics.